Sweden Living World Business Sports Entertainment

Novo Nordisk shares fall about 10% after negative phase 3 trial news on Ziltivekimab

Published: Fri 31 Jul 2026 13:28 CEST

Photo: Richard Drew/AP/TT

Danish pharmaceutical giant Novo Nordisk is plunging by around 10 percent on the Copenhagen Stock Exchange after negative news regarding a phase 3 clinical trial linked to the drug candidate Ziltivekimab.

Author

By TT News Agency. English edition by Sweden Herald, adapted for our readers

Keep reading

Loading related posts...

Novo Nordisk shares fall about 10% after negative phase 3 trial news on Ziltivekimab

Most read articles

Volvo Cars to close Stockholm office, 450 employees affected

Marius Borg Høiby among pallbearers carrying King Harald’s coffin through Oslo palace

Åkesson repeats demand for clarity from Busch on possible S-led government support

Russian city of Belgorod hit by deadly rocket attack, 2 killed and 16 injured